Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Hepatol Res. 2014 Jun 4;45(3):305–314. doi: 10.1111/hepr.12352

Figure 5.

Figure 5

Delayed treatment with amitriptyline reduces activated hepatic stellate cells and reduces portal hypertension after established hepatic fibrosis. (A) Representative samples of α-SMA immunohistochemical staining (magnification 50X) reveals decreased activated HSC burden by week 15 in animals that treated with amitriptyline (TCA) in a delayed fashion (after 5 weeks of treatment with CCl4) vs. animals treated with CCl4 alone. (B) Animals treated with CCl4 alone had more significant splenomegaly, reflective of their progressive liver disease, relative to the animals treated with CCl4 and TCA in a delayed fashion. n=4–6 per group. Data are expressed as mean and SEM. *p<0.05 compared to CCl4 alone group.